| Literature DB >> 35572877 |
Nozomu Motono1, Masahito Ishikawa1, Shun Iwai1, Yoshihito Iijima1, Hidetaka Uramoto1.
Abstract
Background: Although several prognostic factors in patients undergoing pulmonary resection with early-stage non-small cell lung cancer (NSCLC) have been reported, the risk factors are varied and have not been consistent among reports.Entities:
Keywords: Early stage; interstitial lung disease; non-small cell lung cancer (NSCLC); wedge resection
Year: 2022 PMID: 35572877 PMCID: PMC9096310 DOI: 10.21037/jtd-21-1757
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Patient characteristics (n=540)
| Characteristics | Value |
|---|---|
| Gender (male/female), n | 310/230 |
| Age (years), median [range] | 70.6 [22–92] |
| Comorbidity, n (%) | 319 (59.1) |
| Interstitial lung disease | 7 (1.3) |
| Malignant disease | 107 (19.8) |
| Angina pectoris | 35 (6.5) |
| Smoking index, median [range] | 400 [0–3,250] |
| CEA (ng/mL), median [range] | 3.0 [0.5–44.0] |
| %VC, median [range] | 100.7 [53.4–177.7] |
| FEV1%, median [range] | 73.9 [30.5–99.4] |
| Lobe of lung cancer (RU/RM/RL/LU/LL), n | 165/33/118/130/94 |
| Operative approach (RATS/C-VATS/H-VATS/open), n | 10/244/267/19 |
| Operative procedure (Wedge/Seg/Lob), n | 131/57/352 |
| Histology (Ad/Sq/LCNEC/Pleo/AdSq/large/carcinoid), n | 454/60/13/3/4/1/5 |
| Lymphatic invasion (present/absent), n | 92/448 |
| Vascular invasion (present/absent), n | 136/404 |
| Differentiation (G1/2/3/4), n | 240/243/45/12 |
| Postoperative complication, n (%) | 127 (23.5) |
| Clavien-Dindo grade (0/1/2/3a/3b), n | 413/0/48/76/3 |
| Thirty-day mortality, n (%) | 1 (0.2) |
| Ninety-day mortality, n (%) | 1 (0.2) |
| Postoperative hospital-stay (days), median [range] | 10 [3–89] |
CEA, carcinoembryonic antigen; %VC, percent-predicted vital capacity; FEV1%, forced expiratory volume % in one second; RU, right upper; RM, right middle; RL, right lower; LU, left upper; LL, left lower; RATS, robot-assisted thoracic surgery; C, complete; VATS, video-assisted thoracic surgery; H, hybrid; Wedge, wedge resection; Seg, segmentectomy; Lob, lobectomy; Ad, adenocarcinoma; Sq, squamous cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; Pleo, pleomorphic carcinoma; AdSq, adenosquamous cell carcinoma; Large, large cell carcinoma; G, grade.
Figure 1RFS for non-small cell lung cancer patients with pathological stage IA. Coexistence of ILD group was significantly worse than the absent of ILD group. RFS, relapse-free survival; ILD, interstitial lung disease.
Figure 2OS for non-small cell lung cancer patients with pathological stage IA. Coexistence of interstitial lung disease group was significantly worse than the absent of interstitial lung disease group. OS, overall survival.
Univariate and multivariate analyses of clinicopathological factors in pathological stage IA NSCLC patients
| Variables | 5-year RFS (%) | Univariate P value | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR | 95% CI | P value | |||
| Gender | 0.676 | – | – | – | |
| Male | 86.3 | ||||
| Female | 88.9 | ||||
| Age | 0.175 | – | – | – | |
| ≤75 years | 85.7 | ||||
| >75 years | 90.8 | ||||
| Comorbidity | – | – | – | ||
| Malignant disease | 0.913 | ||||
| Present | 90.5 | ||||
| Absent | 86.8 | ||||
| Interstitial lung disease | <0.0001 | 7.725 | 2.144–21.776 | 0.003 | |
| Present | 33.3 | ||||
| Absent | 88.2 | ||||
| Angina pectoris | 0.651 | – | – | – | |
| Present | 88.7 | ||||
| Absent | 87.3 | ||||
| Smoking history | 0.140 | – | – | – | |
| Present | 86.3 | ||||
| Absent | 88.7 | ||||
| %VC | 0.611 | – | – | – | |
| <80 | 92.9 | ||||
| ≥80 | 87.0 | ||||
| FEV1% | 0.209 | – | – | – | |
| <70 | 85.5 | ||||
| ≥70 | 88.2 | ||||
| CEA | 0.006 | 1.923 | 1.015–3.518 | 0.045 | |
| >5 ng/mL | 79.0 | ||||
| ≤5 ng/mL | 89.9 | ||||
| Operative approach | 0.331 | – | – | – | |
| C-VATS or RATS | 82.4 | ||||
| H-VATS or Open | 88.7 | ||||
| Operative procedure | 0.002 | 2.086 | 1.100–3.825 | 0.025 | |
| Wedge resection | 81.1 | ||||
| Segmentectomy or more | 89.2 | ||||
| Postoperative complication | 0.641 | – | – | – | |
| Present | 84.6 | ||||
| Absent | 88.1 | ||||
| Lymphatic invasion | 0.086 | – | – | – | |
| Present | 81.9 | ||||
| Absent | 88.6 | ||||
| Vascular invasion | 0.120 | – | – | – | |
| Present | 82.3 | ||||
| Absent | 89.2 | ||||
| Differentiation | 0.101 | – | – | – | |
| G1 or 2 | 85.4 | ||||
| G3 or 4 | 82.6 | ||||
NSCLC, non-small cell lung cancer; RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; %VC, percent-predicted vital capacity; FEV1%, forced expiratory volume % in one second; CEA, carcinoembryonic antigen; C, complete; VATS, video-assisted thoracic surgery; RATS, robot-assisted thoracic surgery; H, hybrid; G, grade.
Univariate and multivariate analyses of clinicopathological factors in pathological stage IA NSCLC patients
| Variables | 5-year OS (%) | Univariate P value | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR | 95% CI | P value | |||
| Gender | 0.344 | – | – | – | |
| Male | 82.0 | ||||
| Female | 86.6 | ||||
| Age | 0.276 | – | – | – | |
| ≤75 years | 82.1 | ||||
| >75 years | 87.2 | ||||
| Comorbidity | |||||
| Malignant disease | 0.913 | – | – | – | |
| Present | 83.1 | ||||
| Absent | 83.7 | ||||
| Interstitial lung disease | 0.0015 | 3.431 | 0.54–11.931 | 0.158 | |
| Present | 62.5 | ||||
| Absent | 84.2 | ||||
| Angina pectoris | 0.575 | – | – | – | |
| Present | 91.4 | ||||
| Absent | 83.4 | ||||
| Smoking history | 0.0003 | 2.539 | 1.372–5.002 | 0.002 | |
| Present | 77.2 | ||||
| Absent | 91.6 | ||||
| %VC | 0.969 | – | – | – | |
| <80 | 89.6 | ||||
| ≥80 | 83.4 | ||||
| FEV1% | 0.293 | – | – | – | |
| <70 | 81.6 | ||||
| ≥70 | 84.7 | ||||
| CEA | <0.0001 | 2.464 | 1.389–4.317 | 0.002 | |
| >5 ng/mL | 68.6 | ||||
| ≤5 ng/mL | 88.5 | ||||
| Operative approach | 0.122 | – | – | – | |
| C-VATS or RATS | 78.1 | ||||
| H-VATS or Open | 85.4 | ||||
| Operative procedure | 0.942 | – | – | – | |
| Wedge resection | 90.0 | ||||
| Segmentectomy or more | 82.7 | ||||
| Postoperative complication | 0.098 | – | – | – | |
| Present | 75.6 | ||||
| Absent | 86.3 | ||||
| Lymphatic invasion | 0.661 | – | – | – | |
| Present | 76.8 | ||||
| Absent | 85.5 | ||||
| Vascular invasion | 0.499 | – | – | – | |
| Present | 78.6 | ||||
| Absent | 85.6 | ||||
| Differentiation | 0.201 | – | – | – | |
| G1 or 2 | 84.5 | ||||
| G3 or 4 | 78.0 | ||||
NSCLC, non-small cell lung cancer; OS, overall survival; HR, hazard ratio; CI, confidence interval; %VC, percent-predicted vital capacity; FEV1%, forced expiratory volume % in one second; CEA, carcinoembryonic antigen; C, complete; H, hybrid; VATS, video-assisted thoracic surgery; G, grade; RATS, robot-assisted thoracic surgery.